Matteo Bellia

ORCID: 0009-0004-9709-4935
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Blood groups and transfusion
  • Hemoglobinopathies and Related Disorders
  • Glycosylation and Glycoproteins Research
  • Immunodeficiency and Autoimmune Disorders
  • Acute Lymphoblastic Leukemia research
  • Erythrocyte Function and Pathophysiology
  • Neonatal Health and Biochemistry
  • Cancer Genomics and Diagnostics
  • Methemoglobinemia and Tumor Lysis Syndrome
  • Lung Cancer Treatments and Mutations
  • Cancer-related gene regulation
  • Viral-associated cancers and disorders

Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2023-2025

Azienda Ospedaliero Universitaria Maggiore della Carita
2024

Circulating tumor DNA (ctDNA) levels can help predict outcomes in diffuse large B-cell lymphoma (DLBCL), but its integration with DLBCL molecular clusters remains unexplored. Using the LymphGen tool 77 both ctDNA and tissue biopsy, a 95.8% concordance rate cluster assignment was observed, showing reproducibility of clustering on ctDNA. A multicenter, prospective cohort 166 newly diagnosed analyzed for using CAPP-seq. Patients < 2.5 log10hGE/mL had 4-year progression-free survival...

10.1182/bloodadvances.2024014136 article EN cc-by-nc-nd Blood Advances 2025-01-18

ABSTRACT Introduction The use of artificial intelligence in hematology laboratories has improved the diagnostic evaluation peripheral blood cells. aim this study is to compare performance two automated digital cell morphology analyzers, Mindray MC‐80 and West Medical Vision Hema Pro, with manual microscopy, gold standard, for leukocyte differentiation patients hematologic malignancies infections. Methods Peripheral smears from 75 were analyzed, including cases acute lymphoblastic leukemia...

10.1111/ijlh.14470 article EN International Journal of Laboratory Hematology 2025-03-27

Summary Here we evaluated the epigenomic and transcriptomic profile of XPO1 mutant chronic lymphocytic leukaemia (CLL) their clinical phenotype. By ATAC‐seq, chromatin regions that were more accessible in mutated CLL enriched binding sites for transcription factors regulated by pathways emanating from B‐cell receptor (BCR), including NF‐κB signalling, p38‐JNK RAS‐RAF‐MEK‐ERK. CLL, consistent with accessibility changes, features associated BCR cytokine signalling. combining data, MIR155HG ,...

10.1111/bjh.19052 article EN cc-by-nc-nd British Journal of Haematology 2023-08-14

Jaundice and hyperbilirubinemia are common clinical problems characterized by the presence of bile pigments in blood their deposition body tissues. This condition can be associated with a broad spectrum potential benign malignant causes, including hepatic inflammation, biliary obstruction, impaired bilirubin conjugation overproduction Therefore, diagnostic work-up sometimes highly challenging its therapeutic management require multidisciplinary approach.

10.2147/imcrj.s477296 article EN cc-by-nc International Medical Case Reports Journal 2024-10-01

The mutational status of immunoglobulin (IG) light chain genes in chronic lymphocytic leukemia (CLL) and its clinical impact have not been extensively studied. To assess their prognostic significance, the IG gene repertoire CLL patients has evaluated using a training-validation approach. In training cohort (N = 573 CLL), 92.5% showed productive rearrangements, with IGKV4-1 (20.5%) IGLV3-21 (19.0%) being most common. A 99.0% somatic hypermutation cut-off was identified as best predictor for...

10.1038/s41375-024-02499-x article EN cc-by-nc-nd Leukemia 2024-12-17

Aim: The aim of the current study was to evaluate potential clinical impact clonal evolution detected by fluorescence in situ hybridization (FISH) untreated chronic lymphocytic leukaemia (CLL) patients managed with a watch-and-wait strategy. Methods: We performed both overall survival (OS) and time first treatment (TTFT) analysis. For one, we exploited real-life cohort 123 consecutive CLL followed at our institution, for which least second FISH evaluation during watch wait available. TTFT...

10.20517/2394-4722.2023.131 article EN Journal of Cancer Metastasis and Treatment 2024-01-15

a-rare-case-of-life-threatening-jaundice-caused-by-abortion-pill-assumptionepstein-barr-infection

10.22541/au.171773811.15814855/v1 preprint EN Authorea (Authorea) 2024-06-07

Background/Objectives: The latest WHO classification underscores the importance of complete blood count (CBC) and cell morphology assessment in diagnosing lymphoid neoplasms. This study evaluated diagnostic role Research Use Only (RUO) parameters from BC-6800 Plus Mindray analyzer differentiating chronic lymphocytic leukemia (CLL), acute lymphoblastic (ALL), other lymphoproliferative disorders. Methods: CBCs were performed on 90 patients (66% male, median age 67 years) with pathological...

10.20944/preprints202408.1254.v1 preprint EN 2024-08-16

A 50-year-old Caucasian woman was admitted to the Hematology Department complaining of abdominal distension and early satiety for 8 months, accompanied by involuntary weight loss 23 kg over past year. Her medical history revealed thalassemia, she had no current or smoking alcohol consumption. Initial examination splenomegaly (25 cm). Laboratory analysis showed a white blood cell count 5.00 × 109/L (normal reference range: 4.50–11 109/L), hemoglobin level 65 g/L 115–135 g/L), platelet 135...

10.1111/ijlh.14378 article EN cc-by-nc-nd International Journal of Laboratory Hematology 2024-10-10

Background: The XPO1 gene, which codes for a nuclear exportin responsible the partitioning of macromolecules essential cell homeostasis, represents one chronic lymphocytic leukemia (CLL) driver genes. In cases mutations negatively charged glutamic acid at position E571 is substituted with positively lysine, thus promoting interaction proteins bearing export signals (NES). Most newly diagnosed CLL patients do not require therapy initially and are managed watch wait strategy. characterized by...

10.1097/01.hs9.0000969292.92780.4e article EN cc-by-nc-nd HemaSphere 2023-08-01
Coming Soon ...